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Neomycin (0.1-l mM) added to human platelet-rich plasma or washed platelets prelabeled with [3H]inositol 
inhibits aggregation, ATP secretion (ID,, 0.2 mM) and formation of [3H]inositol mono-, bis- and trisphos- 
phate (ID,, 060.8 mM) in response to thrombin (0.25 U/ml). The production of inositol phosphates in 
response to other platelet agonists (vasopressin, platelet activating factor, prostaglandin endoperoxide ana- 
logs and collagen) is not inhibited by neomycin, even at a concentration of 2 mM. At this concentration 
neomycin reduces the secretion of ATP stimulated by these agents (by up to 50%). The results indicate that 
neomycin has multiple effects on platelets that are unrelated to a specific inhibition of inositol phospholipid 
degradation by phospholipase C. Low concentrations (0. l-l mM) of neomycin might selectively inhibit the 
interaction of thrombin with the platelet surface, and high concentrations (> 2 mM) might unspecifically 
reduce platelet secretion in response to various platelet agonists. 
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1. INTRODUCTION 
Neomycin, an ototoxic and nephrotoxic polyca- 
tionic drug, has been shown to interact with 
anionic phospholipids such as the polyphos- 
phoinositides [l-3]. Neomycin binds to phos- 
phatidylinositol 4,Sbisphosphate [4,51, the 
degradation of which by phospholipase C leads to 
the formation of the second messengers: l,Zdia- 
cylglycerol and inositol (Ins) 1,4,Strisphosphate 
(P3) [6,7]. Neomycin decreases “P-labeling and 
the mass of phosphatidylinositol 4,5-bisphosphate 
in various biological systems [2,3,8] and inhibits 
renal phosphatidylinositol-specific phospholipase 
C at low concentrations (IDso 0.03 mM) [9]. These 
effects of neomycin have been used to study the 
relevance of the inositol phospholipid metabolism 
for the mechanism of signal transduction in 
various cells. For example, neomycin has been 
found to block Ca2+-dependent histamine secre- 
tion from mast cells [lo], excitation-contraction 
Inositolphosphates Thrombin Phospholipase C 
coupling in skeletal muscle [ 111, carbachol-induced 
amylase secretion in permeabilized pancreatic acini 
[ 121 and thrombin-induced cell proliferation of 
hamster fibroblasts [ 13 1. However, concurrent 
determinations of inositol phospholipid degrada- 
tion were carried out in only a few studies [12,13], 
and in none of them was more than one agonist 
used. Recently, neomycin was also shown to bind 
specifically to Ins 1,4,5-P3, thus inhibiting 
Ca2+-mobilization [ 141. This questioned the 
usefulness of neomycin as a specific inhibitor for 
the degradation of the inositol phospholipids. 
Inositol phospholipid hydrolysis by phos- 
pholipase C is observed in platelets in response to 
many stimuli [15]. We have studied the effect of 
neomycin on inositol phospholipid metabolism 
and platelet function, and found that low concen- 
trations of neomycin inhibited selectively the ac- 
tion of thrombin on platelets, but not that of other 
agonists. 
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2. MATERIALS AND METHODS 
2.1. Materials 
Neomycin sulfate was obtained from Sigma (St. 
Louis, MO) and was dissolved in Hz0 as a 200 mM 
stock solution. [3H]Inositol was obtained from 
Amersham and was purified before use [16]. y- 
Thrombin was a gift from Dr J.W. Fenton 
(Albany, NY). Acetylsalicylic acid was from Sigma 
and was dissolved as a 1 M stock solution in 
ethanol. All other materials were obtained as 
described [ 16,171. 
2.2. Methods 
Citrated (0.38%) platelet-rich plasma was ob- 
tained from healthy human volunteers. Platelet ag- 
gregation and ATP secretion were measured with 
a Lumi-Aggregometer@ (Chrono-Log, Haver- 
town, PA). Neomycin was added 1 min before the 
platelet agonist to 0.44 ml of platelet-rich plasma 
containing 0.04 ml of the Luciferase/Luciferin 
reagent. 
The production of [3H]inositol phosphates in 
stimulated platelets was determined as described 
[18,19]. Platelet-rich plasma from 200 ml of 
titrated blood was incubated with aspirin (1 mM) 
for 15 min at 37°C and centrifuged (800 x g for 
10 min) after addition of prostacyclin (50 ng/ml). 
The platelets were resuspended in 3 ml of a buffer 
containing Hepes (20 mM), NaCl (138 mM), 
NaHzPOd. H20 (3.3 mM), KC1 (2.9 mM), EGTA 
(1 mM), MgC12 (1 mM), apyrase (6 units 
ADPase/ml), glucose (5 mM), prostacyclin 
(500 ng/ml) and [3H]inositol (0.6 mCi/ml). The 
platelet suspension was incubated at 37’C for 3 h 
in a water bath. The pH during that period was 
controlled, and adjusted every 30 min with 1 N 
NaOH. Platelets were then centrifuged and 
resuspended in 10 ml of a Hepes-salt buffer con- 
taining glucose (5 mM), CaC12 (0.1 mM), MgClz 
(1 mM), creatine phosphate (2 mM) and creatine 
phosphokinase (20 p/ml). The platelet suspension 
was kept at 37°C for 60 min before beginning the 
experiment. Samples of platelet suspension were 
placed into aggregometer tubes and platelets were 
incubated with neomycin or saline whilst stirring 
for 1 min before exposure to the platelet agonists. 
After 1 min, or 1.5 min if collagen was used, the 
samples were transferred into chloroform/ 
methanol/cone. HCl (100 : 200: 2). The [3H]ino- 
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sitol phosphates were extracted and separated on 
Dowex anion-exchange columns as described [191. 
The fractions containing the inositol mono-, bis- 
and trisphosphates, respectively, were measured 
for radioactivity by liquid scintillation counting. 
3. RESULTS 
3.1. Effects of neomycin on platelet-rich plasma 
Addition of neomycin to platelet-rich plasma ef- 
fectively inhibits aggregation and secretion in- 
duced by thrombin or y-thrombin (fig.1). ATP 
secretion is inhibited by lower concentrations of 
neomycin (IDso -0.2 mM) than platelet aggrega- 
tion (ID50 -0.7 mM). Concentrations of neomycin 
(l-l .5 mM) that inhibit ATP secretion by more 
than 90% lead to a reversible aggregation response 
by thrombin. A concentration of 2 mM neomycin 
blocks aggregation and secretion completely but 
not shape change. Platelet shape change can, 
however, be blocked by 5 mM neomycin. The ef- 
fect of neomycin is almost instantaneous and it is 
observed when added 5 s before thrombin. 
Aspirin-treatment of platelet-rich plasma does not 
reduce platelet sensitivity to neomycin. 
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Fig. 1. Inhibition of thrombin-induced responses of 
platelets in plasma by neomycin. Aspirinized or non- 
aspirinized platelet-rich plasma was incubated with 
neomycin for 1 min and stimulated with thrombin 
(0.25 U/ml) or y-thrombin (90 nM) for 1 min. The 
results are means f SD from 5 experiments and 
expressed as % of the thrombin-induced response in the 
absence of neomycin (44 f 5% light transmission and 
12 f 2 nmol ATP secretion per lo9 platelets). 
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Fig.2. Effect of neomycin (2 mM) on aggregation and 
secretion of platelets in plasma stimulated by various 
agonists. Results (means f SD) are from 4 experiments. 
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The responses of platelet-rich plasma to other 
agonists such as platelet-activating factor, ADP, 
vasopressin, epinephrine and collagen is not af- 
fected by neomycin (0. l-l mM). The aggregation 
response to these platelet agonists is not reduced by 
high concentrations (2 mM) of neomycin, but a 
reduction of ATP secretion (up to 50%) is ob- 
served (fig.2). 
3.2. Effects of neomycin on washed platelets 
The effects of neomycin on the production of 
[3H]inositol phosphates in washed platelets 
stimulated by thrombin are shown in fig.3. The 
platelets were aspirinized. The suspension buffer 
contained creatine phosphate/creatine phos- 
phokinase to exclude effects of neomycin on 
platelet arachidonate metabolism and ADP 
release. Neomycin inhibits in a dose-dependent 
fashion the formation of InsPi, InsPz and InsP3 
induced by thrombin. A concentration of 0.1 mM 
neomycin significantly inhibits inositol phosphate 
production, aggregation and ATP release caused 
by 0.25 units/ml thrombin (fig.3). Aggregation 
and ATP secretion in washed platelets are more ef- 
fectively inhibited by neomycin (ID50 -0.2 mM) 
than the production of the inositol phosphates 
(ID50 -0.6-0.8 mM). Fig.3 also illustrates that 
there is no preferential inhibition of any of the in- 
ositol phosphates by neomycin. 
Table 1 shows that the inositol phosphate pro- 
duction induced by collagen, vasopressin, PAF 
and prostaglandin endoperoxide analogs is not in- 
hibited by 2 mM neomycin. Neomycin, however, 
reduces the secretion of ATP induced by those 
agonists by as much as 50% (table 1). 
Fig.3. Dose-dependent inhibition of thrombin-induced 
platelet responses and inositol phosphate formation by 
neomycin. Platelet suspension prelabeled with 
[3H]inositol were incubated with neomycin for 1 min 
and then with thrombin (0.25 U/ml) for 1 min. 
[3H]Inositol phosphates were extracted and separated by 
Bio-Rad@ columns as described in section 2. The ranges 
of inositol phosphate formation induced by thrombin in 
the absence of neomycin were 1000-3000 cpm for InsPi, 
700-2200 cpm for InsP2 and 200-450 cpm for InsP3. 
Results are shown as means f SD from 4 experiments. 
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Table 1 
Effect of neomycin (2 mM) on platelet inositol 
phosphate production and ATP secretion induced by 
various agonists 
3H radioactivity ATP secre- 
(cpm) tion (nmol 
per 10’ 
InsPI InsPz InsP3 platelets) 
Control 2600 707 174 0 
Neomycin 2643 655 165 0 
Thrombin, 0.25 U/ml 3876 1460 427 134 
+ neomycin 2901 1002 243 2 
PAF, 1 pM 2960 801 207 8 
+ neomycin 2992 793 200 3 
Collagen, 25 pg/ml 3481 1292 305 43 
+ neomycin 3507 1380 302 24 
Vasopressin, 1 PM 2970 872 201 7 
+ neomycin 3105 819 187 4 
U44069, 1 PM 3057 896 183 18 
+ neomycin 2974 882 176 4 
For details see section 2. Mean of duplicate 
determinations of a typical experiment is shown 
4. DISCUSSION 
Neomycin (0.1-l mM) selectively inhibits in- 
ositol phosphate production, aggregation and 
secretion induced by thrombin but not that caused 
by other platelet agonists. This agonist-selective 
platelet inhibition may indicate that neomycin acts 
prior to a general transduction mechanism. Activa- 
tion of platelet proteases has been implicated in the 
mechanism of platelet activation by thrombin and 
trypsin [20]. Neomycin does not block trypsin- 
induced responses in platelets (unpublished), 
which indicates that neomycin probably does not 
affect platelet proteases. Neomycin most probably 
alters the interaction of thrombin with the platelet 
surface. This interaction is complex and involves at 
least two glycoproteins, glycoprotein Ib and V. 
Glycoprotein Ib might serve as the binding site for 
thrombin [21]; glycoprotein V is proteolytically 
cleaved by thrombin [22,23]. Studies using cy- and 
y-thrombin provide evidence for two types of 
thrombin receptors and coupling mechanisms [24]. 
Because neomycin blocks the a&ion of y- 
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thrombin, the coupling mechanism involved with 
this receptor [24] might be affected by neomycin. 
Platelet phospholipase C degrades all inositol 
phospholipids [ 15,25,26]. Since neomycin binds in 
vitro especially to phosphatidylinositol 4,5-bis- 
phosphate [4,5], a selective inhibition of InsP3 for- 
mation would have been expected. The fact that 
neomycin inhibited InsPI, InsPz and InsPJ forma- 
tion in response to thrombin to the same degree 
supports the idea that neomycin inhibits the action 
of thrombin at a level prior to the activation of 
phospholipase C. 
Thrombin-induced platelet responses are in- 
hibited by neomycin more effectively than the pro- 
duction of inositol phosphates. For example at a 
concentration of 0.5 mM neomycin, platelet ag- 
gregation and ATP secretion are inhibited by 75%) 
but the formation of inositol phosphates is only in- 
hibited by 40-50% (fig.3). This lack of an exact 
correlation between platelet responses and inositol 
phosphate formation is also observed with other 
platelet agonists (table 1). Neomycin (2 mM) 
reduced the secretion response to a number of 
agonists without inhibiting the inositol phosphate 
production (table 1). This could indicate that 
neomycin inhibits platelet secretion at steps which 
are distal to the production of inositol phosphates. 
One of those steps could be the inhibition of Ins 
1,4,5-P3 induced Ca’+ mobilization by neomycin 
[141. 
In conclusion, our results show that neomycin 
has multiple effects on platelets that are unrelated 
to an interaction of that drug with inositol 
phospholipids. 
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